Shattuck Labs, Inc.
Business
Shattuck Labs is a clinical-stage biotechnology company developing monoclonal and bispecific antibodies targeting the DR3/TL1A immune pathway for inflammatory and immune-mediated diseases. The company's lead program, SL-325, is a potentially first-in-class DR3 blocking antibody in Phase 1 clinical development for inflammatory bowel disease and other indications. Additional pipeline candidates include SL-425, a half-life extended version of SL-325, and preclinical DR3-based bispecific antibodies designed to target DR3 and other clinically validated immune targets.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 | FY 2020 2020-12-31 |
|---|---|---|---|---|---|
| Revenue from Contract with Customer, Product and Service [Extensible List] | — | — | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 54 | 57 | 126 | 47 | 92 | |
| Investments | 24 | 16 | 5 | — | — | |
| Prepaid expenses and other current assets | 4 | 6 | 13 | 23 | 19 | |
| Total current assets | 82 | 79 | 143 | 185 | 288 | |
| Property and equipment, net | 6 | 10 | 14 | 18 | 10 | |
| Investment in related party | 1 | 0 | — | — | — | |
| Other assets | 1 | 2 | 3 | 3 | 381,000 | |
| Total assets | 91 | 91 | 160 | 205 | 299 | |
| Accounts payable | 2 | 2 | 2 | 7 | 10 | |
| Accrued expenses and other current liabilities | 5 | 6 | 10 | 18 | 15 | |
| Total current liabilities | 7 | 9 | 11 | 25 | 25 | |
| Non-current operating lease liabilities | 2 | 3 | 3 | 4 | 0 | |
| Total liabilities | 9 | 11 | 15 | 29 | 27 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Common stock, $0.0001 par value: 300,000,000 shares authorized, 63,279,843 shares issued and outstanding at December 31, 2025 and 47,714,708 shares issued and outstanding at December 31, 2024 | 7,000 | 5,000 | 5,000 | 5,000 | 5,000 | |
| Additional paid-in capital | 513 | 461 | 451 | 396 | 389 | |
| Accumulated other comprehensive income | 6,000 | 2,000 | 4,000 | −877,000 | −560,000 | |
| Accumulated deficit | −431 | −382 | −306 | −219 | −117 | |
| Total stockholders equity | 82 | 80 | 145 | 176 | 272 | |
| Total liabilities and stockholders equity | 91 | 91 | 160 | 205 | 299 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 7 | 10 | 7 | 6 | 5 | |
| Depreciation | 4 | 4 | 4 | 3 | 1 | |
| Non-cash operating lease expense | 506,000 | 428,000 | 364,000 | 302,000 | 0 | |
| Impairment loss of fixed assets | 81,000 | 222,000 | — | — | — | |
| Non-cash license revenue | −1 | 0 | — | — | — | |
| Net amortization of investments | −453,000 | −2 | −1 | 1 | 3 | |
| Gain on lease modification | −100,000 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 2 | 6 | 10 | −4 | −9 | |
| Other assets | 79,000 | 90,000 | 165,000 | −53,000 | −32,000 | |
| Accounts payable | −318,000 | 832,000 | −6 | −3 | 8 | |
| Accrued expenses and other current liabilities | −1 | −3 | −8 | 3 | 7 | |
| Non-current operating lease liabilities | −922,000 | −900,000 | −796,000 | −702,000 | 0 | |
| Net cash used in operating activities | −40 | −61 | −81 | −94 | −57 | |
| Sales and maturities of investments | 36 | 85 | 191 | 193 | 202 | |
| Purchases of investments | −43 | −94 | −80 | −132 | −204 | |
| Purchase of property and equipment | −71,000 | −59,000 | −407,000 | −12 | −8 | |
| Net cash used in investing activities | −8 | −9 | 111 | 49 | −10 | |
| Proceeds from sale of common stock, pre-funded warrants and common stock warrants, net of offering costs | 44 | — | 48 | 0 | — | |
| Proceeds from sale of common stock, pre-funded warrants and common stock warrants, net of offering costs | — | −17,000 | — | — | — | |
| Proceeds from the exercise of common stock warrants | 139,000 | 0 | — | — | — | |
| Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan | 25,000 | 1 | 499,000 | 171,000 | 2 | |
| Taxes paid related to net share settlement of equity awards | −65,000 | −451,000 | −53,000 | 0 | — | |
| Net cash provided by financing activities | 45 | 787,000 | 49 | 171,000 | 2 | |
| Decrease in cash and cash equivalents | −3 | −68 | 78 | −45 | −66 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Shattuck Labs, Inc.'s CIK number?
Shattuck Labs, Inc.'s SEC CIK number is 0001680367 (1680367). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Shattuck Labs, Inc.'s SEC filings?
All of Shattuck Labs, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Shattuck Labs, Inc. last report earnings?
Shattuck Labs, Inc. (STTK) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-031643). This is Shattuck Labs, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Shattuck Labs, Inc.'s most recent earnings 8-K?
Shattuck Labs, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001628280-26-031643. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Shattuck Labs, Inc.'s latest earnings 8-K →
Look up any company's CIK number →